Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties

Autor: Motahareh Mortazavi, Masoomeh Eskandari, Fatemeh Moosavi, Tahereh Damghani, Mehdi Khoshneviszadeh, Somayeh Pirhadi, Luciano Saso, Najmeh Edraki, Omidreza Firuzi

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-17 (2023)

Abstract Oncogenic activation of receptor tyrosine kinases (RTKs) such as MET is associated with cancer initiation and progression. We designed and synthesized a new series of quinazoline derivatives bearing 1,2,3-triazole moiety as targeted anticanc

Externí odkaz: https://doaj.org/article/c1443f8e9a85470f9474abe6d0ecf7b6

Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors

Autor: Motahareh Mortazavi, Masoumeh Divar, Tahereh Damghani, Fatemeh Moosavi, Luciano Saso, Somayeh Pirhadi, Mehdi Khoshneviszadeh, Najmeh Edraki, Omidreza Firuzi

Publikováno v: Frontiers in Chemistry, Vol 10 (2022)

The advent of novel receptor tyrosine kinase inhibitors has provided an important therapeutic tool for cancer patients. In this study, a series of quinazolinone hydrazide triazole derivatives were designed and synthesized as novel MET (c-MET) recepto

Externí odkaz: https://doaj.org/article/cf100fbfe3654206af7467a5ea561e43

Rational Design, Synthesis, In Vitro, and In Silico Studies of Dihydropyrimidinone Derivatives as β-Glucuronidase Inhibitors

Autor: Somaye Karimian, Yasaman Moghdani, Mahsima Khoshneviszadeh, Somayeh Pirhadi, Aida Iraji, Mehdi Khoshneviszadeh

Publikováno v: Journal of Chemistry, Vol 2021 (2021)

In the current study, a series of dihydropyrimidinone derivatives were rationally designed as β-glucuronidase inhibitors. These designed compounds were successfully synthesized and characterized through various spectroscopic techniques such as IR, 1

Externí odkaz: https://doaj.org/article/15a9815137694439bc6e597f5e10ffa5

Alignment independent 3D-QSAR, quantum calculations and molecular docking of Mer specific tyrosine kinase inhibitors as anticancer drugs

Autor: Fereshteh Shiri, Somayeh Pirhadi, Jahan B. Ghasemi

Publikováno v: Saudi Pharmaceutical Journal, Vol 24, Iss 2, Pp 197-212 (2016)

Mer receptor tyrosine kinase is a promising novel cancer therapeutic target in many human cancers, because abnormal activation of Mer has been implicated in survival signaling and chemoresistance. 3D-QSAR analyses based on alignment independent descr

Externí odkaz: https://doaj.org/article/0ea1179791774ceea0f2485dad000c4b

Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library

Autor: Motahareh, Mortazavi, Elaheh, Raufi, Tahereh, Damghani, Mehdi, Khoshneviszadeh, Najmeh, Edraki, Masoomeh, Eskandari, Elisa, Giovannetti, Godefridus J, Peters, Somayeh, Pirhadi, Omidreza, Firuzi

Publikováno v: European Journal of Pharmacology, 938:175395. Elsevier
Mortazavi, M, Raufi, E, Damghani, T, Khoshneviszadeh, M, Edraki, N, Eskandari, M, Giovannetti, E, Peters, G J, Pirhadi, S & Firuzi, O 2023, ' Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library ', European Journal of Pharmacology, vol. 938, 175395 . https://doi.org/10.1016/j.ejphar.2022.175395

c-Met receptor tyrosine kinase has recently emerged as an important target with therapeutic implications in pancreatic cancer. In this study, we carried out a docking virtual screening on an in-house library of 441 synthesized compounds and selected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089ce2b33156cdf9dd873c90dd6d289d
http://www.scopus.com/inward/record.url?scp=85143162338&partnerID=8YFLogxK